文献速递胸部肿瘤

Vebreltinib治疗携带c-Met外显子14跳跃突变的晚期非小细胞肺癌:多中心、单臂、II期KUNPENG研究

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
PubMed 文献 · J Clin Oncol · 2024-07-26

KUNPENG研究是一项多中心、多队列、开放标签、单臂II期试验,评估高选择性MET抑制剂vebreltinib在携带MET外显子14跳跃突变的晚期非小细胞肺癌患者中的疗效与安全性。队列1共纳入52例患者,客观缓解率达75%,疾病控制率96.2%,中位缓解持续时间15.9个月,中位无进展生存期14.1个月,中位总生存期20.7个月。常见治疗相关不良事件为外周水肿、QT间期延长和血肌酐升高。

要点

  • Vebreltinib在MET外显子14跳跃突变晚期NSCLC中客观缓解率达75%。
  • 初治患者客观缓解率77.1%,经治患者70.6%。
  • 中位缓解持续时间15.9个月,中位无进展生存期14.1个月。

核心结论

  • Vebreltinib在MET外显子14跳跃突变非小细胞肺癌患者中显示出有前景的疗效和良好的安全性。

研究设计与样本

  • 多中心、多队列、开放标签、单臂II期试验,2020年1月至2022年8月从17个中心入组携带c-Met异常的局部晚期或转移性非小细胞肺癌患者。
  • 队列1纳入未接受过MET抑制剂的MET外显子14跳跃突变非小细胞肺癌患者,共52例,其中35例(67.3%)为初治患者。
  • Vebreltinib给药剂量为200 mg每日两次,28天为一个周期。
  • 主要终点为客观缓解率,关键次要终点为缓解持续时间,均由盲态独立评审委员会依据RECIST 1.1版评估。

主要发现

  • 截至2022年8月9日,队列1共入组52例患者,其中35例(67.3%)为初治患者。
  • 总体客观缓解率为75%(95% CI,61.1至86)。
  • 初治患者客观缓解率为77.1%(95% CI,59.9至89.6),经治患者客观缓解率为70.6%(95% CI,44.0至89.7)。
  • 疾病控制率为96.2%,中位缓解持续时间为15.9个月,中位无进展生存期为14.1个月,中位总生存期为20.7个月。
  • 最常见的治疗相关不良事件为外周水肿(82.7%)、QT间期延长(30.8%)和血肌酐升高(28.8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The KUNPENG study aimed to evaluate the efficacy and safety of vebreltinib (also known as bozitinib, APL-101, PLB-1001, and CBT-101), a potent and highly selective inhibitor of c-mesenchymal-epithelial transition (MET), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring c-Met alterations. METHODS: This multicenter, multicohort, open-label, single-arm, phase II trial enrolled patients with c-Met dysregulated, locally advanced or metastatic NSCLC from January 2020 to August 2022 across 17 centers. Cohort 1 included patients with MET exon 14 skipping (METex14)-mutant NSCLC who had not previously received MET inhibitors. Participants were administered vebreltinib at a dosage of 200 mg twice a day in 28-day cycles. The primary end point was the objective response rate (ORR), and the key secondary end point was the duration of response (DoR), both evaluated by a blinded independent review committee according to the RECIST version 1.1. RESULTS: As of August 9, 2022, 52 patients had been enrolled in cohort 1, of whom 35 (67.3%) were treatment-naïve. The ORR reached 75% (95% CI, 61.1 to 86). Among treatment-naïve patients, the ORR was 77.1% (95% CI, 59.9 to 89.6), and in previously treated patients, it was 70.6% (95% CI, 44.0 to 89.7). The disease control rate was 96.2%, with a median DoR of 15.9 months, a median progression-free survival of 14.1 months, and a median overall survival of 20.7 months. The most common treatment-related adverse events were peripheral edema (82.7%), QT prolongation (30.8%), and elevated serum creatinine (28.8%). CONCLUSION: Vebreltinib has shown promising efficacy and a favorable safety profile in patients with METex14-mutant NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JJ, Zhang Y, Wu L, et al. Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study. J Clin Oncol. 2024. PMID: 39058972. doi:10.1200/JCO.23.02363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。